Panacea Biotec Secures Significant UNICEF Contract for Polio Vaccine Supply

Panacea Biotec Ltd. has announced a major strategic development, having secured a Letter of Award from the United Nations International Children’s Emergency Fund (UNICEF) for the supply of its bivalent Oral Polio Vaccine (bOPV). Key Highlights for Investors: Contract Value: The award holds a substantial value of approximately $35.65 million (₹315 crore) for the initial supply period covering Q2 CY2026 and the full calendar year of 2027. Long-Term Revenue Visibility: This award is part of a broader Long-Term Agreement (LTA) with UNICEF, spanning from April 1, 2026, to March 31, 2030. This LTA establishes a long-term partnership and provides a strong foundation for potential future orders, enhancing the company's revenue pipeline and business predictability. Global Validation: Securing a contract with a prestigious international body like UNICEF reaffirms Panacea Biotec's manufacturing quality, competitive pricing, and position as a key supplier in the global vaccine market. Market Confidence: The announcement was met with a positive market response, as shares of Panacea Biotec Ltd. closed at ₹415.00 on the BSE, reflecting a notable increase of ₹12.85, or 3.20%. Governance: The company has confirmed the transaction is at arm's length and does not fall under related-party transactions. This development is a significant positive catalyst, reinforcing Panacea Biotec's robust order book and its critical role in global immunization programs. It underscores the company's operational strength and brightens its long-term growth outlook.